Amphastar Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while First Trust Cloud Computing ETF trades at $138.17. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SKYY | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $155.17 |
52-Week Low | $16.87 | $104.16 |
Enterprise Value | $1.22B | — |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SKYY (First Trust Cloud Computing ETF) trades at $139.77, down 1.47% today, with strong technical momentum indicated by bullish moving averages. The ETF provides diversified exposure to cloud computing companies amid growing enterprise AI adoption. Recent news highlights continued institutional interest in technology ETFs and cloud computing sector strength.
The outlook remains positive as cloud computing benefits from enterprise digital transformation and AI spending acceleration. Key risks include sector concentration and technology volatility. Analyst coverage suggests the ETF offers strategic exposure to a high-growth technology segment with institutional-grade market positioning.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →